Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
All content for Beyond the Endpoint is the property of Duke Clinical Research Institute and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
Caring Through Loss: The Role of Grief in Clinical Settings
Beyond the Endpoint
34 minutes 56 seconds
10 months ago
Caring Through Loss: The Role of Grief in Clinical Settings
In this episode of "Beyond the Endpoint," hosts Emily O'Brien and Manesh Patel are joined by guest host Jenny Cook to discuss grief among healthcare providers with Tony Galanos, a researcher and physician at the Duke University School of Medicine. Galanos — "Dr. G" as he's called around Duke — shares insights from his 12-year program helping other clinicians to address and process the grief that can be an inevitable part of their work. He highlights the emotional toll that healthcare work can take and the importance of acknowledging and processing grief. The episode explores the concept of the "hidden curriculum" in medical training, the practice of "the pause" after intense resuscitation efforts, and also dives into how everyone can better manage their own grief after losing a loved one.
🔗 Access resources related to this episode https://dcri.org/blog/ep-1-caring-through-loss-role-grief-clinical-settings
Beyond the Endpoint
Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
